Francis Lee

US Patent:

7169568, Jan 30, 2007

Filed:

Oct 19, 2001

Appl. No.:

09/982095

Inventors:

Moses V. Chao - New York NY, US
Francis S. Lee - San Francisco CA, US

Assignee:

New York University - New York NY

International Classification:

G01N 33/567

US Classification:

435 721

Abstract:

The present invention is directed to a method for screening and identifying molecules that transactivate a neurotrophin receptor and mediate neuronal cell survival in the absence of neurotrophins which uses one or a combination of three different assays. The assays involve detecting the phosphorylation of a neurotrophin receptor, detecting the phosphorylation of phosphotidylinositol 3′-kinase or Akt enzyme, and assessing neuronal cell survival in the absence of neurotrophins.

US Patent:

7504211, Mar 17, 2009

Filed:

Aug 26, 2003

Appl. No.:

10/648593

Inventors:

Fei Huang - Princeton NJ, US
Xia Han - Somerset NJ, US
Karen A. Reeves - Ewing NJ, US
Lukas C. Amler - Pennington NJ, US
Craig R. Fairchild - Yardley PA, US
Francis Y. Lee - Yardley PA, US
Peter Shaw - Yardley PA, US

Assignee:

Bristol-Myers Squibb Company - Princeton NY

International Classification:

C12Q 1/00
C12Q 1/68

US Classification:

435 6, 435 4

Abstract:

The present invention describes polynucleotides that have been discovered to correlate to the relative sensitivity or resistance of cells, e. g. , breast cell lines, to treatment with compounds that interact with and modulate, e. g. , inhibit, protein tyrosine kinases, such as, for example, members of the Src family of tyrosine kinases, e. g. , Src, Fgr, Fyn, Yes, Blk, Hck, Lck and Lyn, as well as other protein tyrosine kinases, including, Bcr-abl, Jak, PDGFR, c-kit and Eph receptors. These polynucleotides have been shown to have utility in predicting the resistance and sensitivity of breast cell lines to the compounds. Such polynucleotides comprise polynucleotide predictor or marker sets useful in methods of predicting drug response, and as prognostic or diagnostic indicators in disease management, particularly in those disease areas, e. g. , breast cancer, in which signaling through one or more of the aforementioned Src tyrosine and protein tyrosine kinases is involved with the disease process.

US Patent:

7537891, May 26, 2009

Filed:

Mar 4, 2005

Appl. No.:

11/072175

Inventors:

Fei Huang - Princeton NJ, US
Xia Han - Pennington NJ, US
Karen A. Reeves - Ewing NJ, US
Lukas C. Amler - Foster City CA, US
Craig R. Fairchild - Yardley PA, US
Francis Y. Lee - Yardley PA, US
Peter Shaw - Yardley PA, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C12Q 1/00
C12Q 1/68

US Classification:

435 6, 435 4

Abstract:

The present invention describes polynucleotides that have been discovered to correlate to the relative sensitivity or resistance of cells, e. g. , breast cell lines, to treatment with compounds that interact with and modulate, e. g. , inhibit, protein tyrosine kinases, such as, for example, members of the Src family of tyrosine kinases, e. g. , Src, Fgr, Fyn, Yes, Blk, Hck, Lck and Lyn, as well as other protein tyrosine kinases, including, Bcr-abl, Jak, PDGFR, c-kit and Eph receptors. These polynucleotides have been shown to have utility in predicting the resistance and sensitivity of breast cell lines to the compounds. Such polynucleotides comprise polynucleotide predictor or marker sets useful in methods of predicting drug response, and as prognostic or diagnostic indicators in disease management, particularly in those disease areas, e. g. , breast cancer, in which signaling through one or more of the aforementioned Src tyrosine and protein tyrosine kinases is involved with the disease process.

US Patent:

8629136, Jan 14, 2014

Filed:

Mar 22, 2012

Appl. No.:

13/426730

Inventors:

Ashvinikumar V. Gavai - Princeton Junction NJ, US
Claude A. Quesnelle - Skillman NJ, US
Soong-Hoon Kim - Titusville NJ, US
Francis Y. Lee - Yardley PA, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07D 243/24
A61K 31/5513
A61P 35/00

US Classification:

514221, 540509

Abstract:

Disclosed are compounds of Formula (I) or prodrugs thereof;.

US Patent:

20050010305, Jan 13, 2005

Filed:

Jan 28, 2004

Appl. No.:

10/766084

Inventors:

Francis Lee - Fort Lee NJ, US

International Classification:

A61F002/28

US Classification:

623023510

Abstract:

A bone graft composite comprising a bisphosphonate is provided which is suitable for treating bone destruction. The bisphosphonate provides bone graft protection.

US Patent:

20060046249, Mar 2, 2006

Filed:

Jan 17, 2003

Appl. No.:

10/501035

Inventors:

Fei Huang - Princeton NJ, US
Craig Fairchild - Yardley PA, US
Francis Lee - Yardley PA, US
Peter Shaw - Yardley PA, US

International Classification:

C12Q 1/68
C07H 21/04

US Classification:

435006000, 536024100

Abstract:

The present invention describes polynucleotides and polypeptides that have been discovered to correlate to the relative intrinsic sensitivity or resistance of cells, e.g., colon cell lines, to treatment with compounds that interact with and inhibit src tyrosine kinases. These polynucleotides and polypeptides have been shown, through a weighted voting cross validation program, to have utility in predicting the intrinsic resistance and sensitivity of colon cell lines to these compounds. Such polynucleotides and polypeptides whose expression levels correlate highly with drug sensitivity or resistance comprise predictor or marker sets of polynucleotides and polypeptides that are useful in methods of predicting drug response, and as prognostic or diagnostic indicators in disease management, particularly in those disease areas in which signaling through src tyrosine kinase of the src tyrosine kinase pathway is involved with the disease process.

US Patent:

20060069101, Mar 30, 2006

Filed:

Sep 26, 2005

Appl. No.:

11/235507

Inventors:

Kyoung Kim - North Brunswick NJ, US
Francis Lee - Yardley PA, US
Louis Lombardo - Belle Mead NJ, US
Feng Luo - Plainsboro NJ, US
John Wityak - Carlsbad CA, US

International Classification:

A61K 31/506
C07D 417/14

US Classification:

514252190, 544295000

Abstract:

Novel compounds and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as oncologic and immunologic disorders.

US Patent:

20070166704, Jul 19, 2007

Filed:

Jan 17, 2003

Appl. No.:

10/348119

Inventors:

Fei Huang - Princeton NJ, US
Craig Fairchild - Yardley PA, US
Francis Lee - Yardley PA, US
Peter Shaw - Yardley PA, US

International Classification:

C12Q 1/68
C07H 21/04

US Classification:

435006000, 536024300

Abstract:

The present invention describes polynucleotides and polypeptides that have been discovered to correlate to the relative intrinsic sensitivity or resistance of cells, e.g., colon cell lines, to treatment with compounds that interact with and inhibit src tyrosine kinases. These polynucleotides and polypeptides have been shown, through a weighted voting cross validation program, to have utility in predicting the intrinsic resistance and sensitivity of colon cell lines to these compounds. Such polynucleotides and polypeptides whose expression levels correlate highly with drug sensitivity or resistance comprise predictor or marker sets of polynucleotides and polypeptides that are useful in methods of predicting drug response and as prognostic or diagnostic indicators in disease management, particularly in those disease areas in which signaling through src tyrosine kinase of the src tyrosine kinase pathway is involved with the disease process.